Welcome to our dedicated page for Nanobiotix S.A. American Depositary Shares news (Ticker: NBTX), a resource for investors and traders seeking the latest updates and insights on Nanobiotix S.A. American Depositary Shares stock.
Nanobiotix S.A. (Euronext: NANO / ISIN: FR0011341205) is a leading clinical-stage nanomedicine company specializing in the development of groundbreaking approaches for cancer treatment. The company's core technology, NanoXray, augments the effectiveness of radiotherapy, offering a more efficient treatment option for cancer patients. The innovative NanoXray products are designed to be compatible with existing radiotherapy treatments and aim to treat a broad spectrum of solid tumors, such as soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, and glioblastoma.
The primary product candidate, NBTXR3, is currently undergoing evaluation for its efficacy in treating soft tissue sarcoma, head and neck cancers, prostate cancer, and liver cancers (both primary and metastases). Additionally, Nanobiotix has partnered with PharmaEngine in Taiwan to conduct trials for head and neck cancer and rectal cancer in the Asia Pacific region.
Nanobiotix has also embarked on a preclinical research program in immuno-oncology, further expanding its portfolio and potential for transformative cancer therapies. NBTXR3 works by magnifying the effects of radiotherapy within tumor cells, thereby enhancing cancer treatment without increasing the dose to surrounding healthy tissues.
Recently, Nanobiotix has been focused on validating the safety and efficacy of RT-activated NBTXR3 by moving to global registration for LA-HNSCC, accounting for the majority of its operational and financial resources. The company plans to provide an updated global development plan for NBTXR3 after further alignment with the Joint Steering Committee (JSC).
In terms of financial performance, Nanobiotix has laid out a cautious strategy, ensuring that it remains well-funded to support ongoing and future operations. Their forward-looking statements highlight the potential risks and uncertainties that could affect their business and financial performance.
For the latest updates, Nanobiotix has scheduled a conference call and webcast on May 22, 2024, at 8:00 am EDT / 2:00 pm CEST. It continues to engage the market, providing transparency to shareholders through various media and regular updates on their progress and milestones.
To keep up with the latest news, visit www.nanobiotix.com.
Nanobiotix (NASDAQ: NBTX) has appointed Bart Van Rhijn as the new CFO, succeeding Philippe Mauberna, who served for eight years. Van Rhijn comes with a strong background in financial management and business development, particularly in the pharmaceutical sector. His leadership is expected to facilitate the launch of the company’s second clinical registration study for NBTXR3 in head and neck cancer and to support expansion in immunotherapy and other solid tumor therapies. Mauberna will remain temporarily to assist during this transition.
NANOBIOTIX (NASDAQ: NBTX), a late-stage biotechnology company, announced that CEO Laurent Levy will present the company's latest developments at the Jefferies Virtual Healthcare Conference on June 4 at 8:00 AM ET (14:00 CET). The event will be available via a live webcast and an archived recording on the company’s website. Nanobiotix focuses on innovative physics-based treatments for cancer and is known for its lead candidate NBTXR3, which has received market authorization in Europe for treating soft tissue sarcoma under the brand name Hensify®.
Nanobiotix (NASDAQ: NBTX) announced the appointment of Dr. Gary Phillips as the new chairman of its supervisory board, succeeding Laurent Condomine. Dr. Phillips brings extensive experience from his roles at OrphoMed and Mallinckrodt Pharmaceuticals. His appointment coincides with the company's strategic focus on advancing its development programs, particularly in head and neck cancer and immunotherapy. Condomine, who led the board for 11 years, oversaw significant milestones, including the launch of NBTXR3, which has received European market authorization. This leadership transition is expected to enhance Nanobiotix's growth trajectory.
Nanobiotix (NASDAQ: NBTX) announced updates at the 2021 ASCO Annual Meeting regarding its leading oncology product NBTXR3 for treating head and neck cancer and advanced cancers. The data shows NBTXR3's potential to enhance the effectiveness of radiotherapy and immunotherapy. In a phase I study, patients with locally advanced head and neck squamous cell carcinoma exhibited an 82.5% objective response rate. The company is set to launch a pivotal phase III trial for NBTXR3 in 2021. Positive long-term safety data from a soft tissue sarcoma study was also reported.
NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX) announced that CEO Laurent Levy will present at the UBS Global Healthcare Virtual Conference on May 24, 2021, at 7:00 AM ET. A live webcast will be available on their website, with a replay to follow. The company, founded in 2003 and headquartered in Paris, focuses on physics-based approaches to cancer treatment. Its lead product, NBTXR3, is authorized in Europe for soft tissue sarcoma under the brand Hensify®.
Nanobiotix (NASDAQ: NBTX) announces a partnership with LianBio to develop NBTXR3, a new cancer treatment, in Greater China and other Asian markets. LianBio will handle commercial development, with Nanobiotix receiving a $20 million upfront payment and potential milestone payments totaling up to $220 million. The collaboration includes participation in a Phase III study for head and neck cancer. NBTXR3 has shown promise in treating solid tumors and has received Fast Track designation from the FDA for certain patient groups.
Nanobiotix (NASDAQ: NBTX) announces a partnership with LianBio to develop NBTXR3, an innovative radioenhancer for cancer treatment, in Greater China and other Asian markets. Nanobiotix will receive a $20 million upfront payment and potential milestone payments of up to $220 million. The agreement allows LianBio to obtain exclusive commercialization rights for NBTXR3, while Nanobiotix continues to fund its global phase III study for head and neck cancer. This strategic collaboration aims to enhance treatment options for cancer patients in the region.
Nanobiotix (NASDAQ: NBTX) reported operational progress and cash position for Q1 2021. The company has €107.1 million in cash, significantly up from €28 million in Q1 2020. Despite this, no revenue was generated in Q1 2021, a drop from €24,000 in Q1 2020 due to the end of a collaboration with PharmaEngine. Notable advancements include promising preclinical data for NBTXR3 and the initiation of a phase I trial in esophageal cancer. Collaborations with Sanofi and the retention of IP rights in the Asia-Pacific region were also highlighted.
NANOBIOTIX (NASDAQ: NBTX) announced it will present new data from its oncology pipeline at the 2021 ASCO Annual Meeting from June 4-8. Four abstracts will showcase NBTXR3, a potential first-in-class radioenhancer, across various tumor types and in combination with anti-PD-1 therapies. Key studies include an updated analysis of NBTXR3 in head and neck cancer, with plans for a global phase III trial in 2021. The company will host a virtual investor event on June 11 to discuss these results.
FAQ
What is the current stock price of Nanobiotix S.A. American Depositary Shares (NBTX)?
What is the market cap of Nanobiotix S.A. American Depositary Shares (NBTX)?
What is Nanobiotix S.A. known for?
What is NanoXray technology?
What types of cancer does NBTXR3 target?
Who is Nanobiotix partnered with in the Asia Pacific region?
What recent projects are Nanobiotix involved in?
When is the next conference call and webcast scheduled?
How does NBTXR3 enhance radiotherapy?
What is the significance of Nanobiotix’s preclinical research program?
Where can I find more information about Nanobiotix?
